Please assess the completion status of the following clinical trial:

Trial Title: Multi-dose Vitamin D Supplementation in Preterm Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Preterm infants with gestational age 24 to 32 weeks who achieved at least 75% of total nutrition by enteral feedings in postnatal 2 weeks~Exclusion Criteria:~* perinatal asphyxia,~* major congenital or chromosomal anomalies,~* those with no expectation of survival in first 2 weeks~* those that total parenteral nutrition was not ceased by the first 2 weeks

- Gender: ALL
- Minimum Age: 24 Weeks
- Maximum Age: 32 Weeks
- Healthy Volunteers: f

Study Arms:
- Devit-3 Oral Drop 400 IU (Type: OTHER): supplemented with oral Vitamin D 400 IU/day (Devit-3 Oral Drop, 50000 IU/15 ml, Deva Company, Turkey) started when achieved 75%of total nutrition by enteral feedings and continued until 36 weeks postmenstrual age
- Devit-3 Oral Drop 800 IU (Type: ACTIVE_COMPARATOR): Devit-3 Oral Drop 800 IU once daily by oral route started when achieved 75%of total nutrition by enteral feedings and continued until 36 weeks postmenstrual age
- Devit-3 Oral Drop 1000 IU (Type: ACTIVE_COMPARATOR): Devit-3 Oral Drop1000 IU once daily by oral route started when achieved 75%of total nutrition by enteral feedings and continued until 36 weeks postmenstrual age

Based on this trial design, predict the completion outcome and termination type (if applicable).